Sergio A. Alanís-Ríos, Celia N. Sánchez-Domínguez, Hiram Villanueva-Lozano, Neri A. Álvarez Villalobos, Rogelio de J. Treviño-Rangel
{"title":"Nanomaterials and Candida auris: A Systematic Review of Emerging Strategies","authors":"Sergio A. Alanís-Ríos, Celia N. Sánchez-Domínguez, Hiram Villanueva-Lozano, Neri A. Álvarez Villalobos, Rogelio de J. Treviño-Rangel","doi":"10.1111/apm.70044","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>The alarming rise of multidrug-resistant <i>Candida auris</i> infections and the consequent scarcity of effective therapeutic options have spurred research into alternative strategies for their prevention and management. Nanomaterials have emerged as a promising avenue for the development of innovative antifungal approaches. A systematic search of MEDLINE, EMBASE, Web of Science, and Scopus databases up to January 3, 2024, was conducted to identify studies reporting on the antifungal efficacy of nanoparticles (NPs) against <i>C. auris</i>. This search included studies on metallic NPs, lipidic carriers, the use of chitosan as a matrix, and other nanoparticle synthesis methodologies, including green chemistry approaches. Of the 266 articles initially retrieved, 30 met the eligibility criteria. Metallic NPs, particularly silver nanoparticles, were the most extensively studied, whereas lipidic carriers were the least explored. All nanomaterials demonstrated antifungal activity, showing inhibition of fungal growth, biofilm disruption, reduced fungal burden, and significantly improved survival rates in animal models of <i>C. auris</i> candidemia. Ongoing research into innovative treatment and prevention strategies remains urgently needed to combat this growing public health threat.</p>\n </div>","PeriodicalId":8167,"journal":{"name":"Apmis","volume":"133 7","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Apmis","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/apm.70044","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The alarming rise of multidrug-resistant Candida auris infections and the consequent scarcity of effective therapeutic options have spurred research into alternative strategies for their prevention and management. Nanomaterials have emerged as a promising avenue for the development of innovative antifungal approaches. A systematic search of MEDLINE, EMBASE, Web of Science, and Scopus databases up to January 3, 2024, was conducted to identify studies reporting on the antifungal efficacy of nanoparticles (NPs) against C. auris. This search included studies on metallic NPs, lipidic carriers, the use of chitosan as a matrix, and other nanoparticle synthesis methodologies, including green chemistry approaches. Of the 266 articles initially retrieved, 30 met the eligibility criteria. Metallic NPs, particularly silver nanoparticles, were the most extensively studied, whereas lipidic carriers were the least explored. All nanomaterials demonstrated antifungal activity, showing inhibition of fungal growth, biofilm disruption, reduced fungal burden, and significantly improved survival rates in animal models of C. auris candidemia. Ongoing research into innovative treatment and prevention strategies remains urgently needed to combat this growing public health threat.
耐多药耳念珠菌感染的惊人增长以及由此导致的有效治疗方案的缺乏,促使人们研究预防和管理这些感染的替代战略。纳米材料已经成为发展创新抗真菌方法的一个有前途的途径。系统检索截至2024年1月3日的MEDLINE、EMBASE、Web of Science和Scopus数据库,以确定纳米颗粒(NPs)对C. auris抗真菌效果的研究报告。这项研究包括对金属纳米粒子、脂质载体、壳聚糖作为基质的使用以及其他纳米粒子合成方法的研究,包括绿色化学方法。在最初检索的266篇文章中,有30篇符合资格标准。金属纳米粒子,尤其是银纳米粒子,被研究得最为广泛,而脂质载体被研究得最少。所有纳米材料都显示出抗真菌活性,显示出抑制真菌生长,破坏生物膜,减少真菌负担,并显着提高耳念珠菌动物模型的存活率。仍然迫切需要对创新治疗和预防战略进行持续研究,以应对这一日益严重的公共卫生威胁。
期刊介绍:
APMIS, formerly Acta Pathologica, Microbiologica et Immunologica Scandinavica, has been published since 1924 by the Scandinavian Societies for Medical Microbiology and Pathology as a non-profit-making scientific journal.